Devicare is getting ready to introduce the Lit-Control® product family (medical device and food supplements) on the French market, thus promoting a domiciliary method for the self-management of frequent urological pathologies through the management and control of urine pH. To this end, Dr François Schutze has recently joined the company as a Country Manager.
Dr François Schutze has acquired vast experience over more than 35 years in the pharmaceutical and biotechnological field holding the following executive responsibilities: CEO at Lidde Therapeutics since 2008, Managing Director at Sonsar-Steba Biotech (2007-2008), CEO at Negma Lerads (1984-2007) —company acquired by the Indian company Wookhardt—, and International Development Director at Ipsen Group (1980-1984). He is an expert in business, lincensing and regulatory development with European and French health authorities (regulations and pricing).
“In June we will begin pre-marketing activities to explain the benefits of Lit-Control® as a first-in-class product that covers an unmet medical need in treatment and prevention of urological diseases in France" explains Schutze. The ultimate objective is to enter into an agreement with a pharmaceutical company and begin distribution in 2018. Currently, Devicare has market presence in Spain through M4 Pharma, and in Mexico with InnovaSalud.
Urological diseases [(Urolithiasis, Urinary Tract Infections (UTIs), Catheter-associated Urinary Tract Infections (CAUTIs), Painful Bladder Syndrome (PBS), interstitial cystitis (IC), Overactive Bladder (OAB)] are the second cause of primary care consultations in Europe.
Miquel González Mut, International Business Development Manager at Devicare comments that: "Prevention is the trend and, as it becomes clearly evident in medical congresses, there is an increasingly widespread consensus on the importance of controlling and monitoring urine pH in the control and management of lithiasis and other pathologies."
